抗体薬物複合体(ADC)のグローバル市場動向

◆英語タイトル:Global Antibody Drug Conjugate Market Outlook 2020
◆商品コード:RNCS507151
◆発行会社(リサーチ会社):RNCOS
◆発行日:2015年7月
◆ページ数:80
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,200 ⇒換算¥133,200見積依頼/購入/質問フォーム
Multi User(全社内共有可)USD1,700 ⇒換算¥188,700見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。

※本調査レポートでは、抗体薬物複合体(ADC)のグローバル市場動向について調査・分析し、以下の構成でお届けいたします。

・抗体薬物複合体(ADC)の概要
・抗体薬物複合体(ADC)の市場展望
・抗体薬物複合体(ADC)パイプライン分析
・抗体薬物複合体(ADC)市場の促進要因・課題
・抗体薬物複合体(ADC)の現状
・抗体薬物複合体(ADC)の市場動向
・競争環境(主要企業分析)
【レポートの概要】

Antibody drug conjugates are the new age therapeutic agents. These are examples of immunoconjugates and bioconjugates. They combine the unique targeting property of monoclonal antibodies and the cancer cell killing ability of cytotoxic drugs. This concept of a “magic bullet” to deliver cytotoxic therapy to the site of a tumor has been envisioned for a century. But its success has become possible only now with the recent technological advancements. The recent approvals of ADCETRIS and Kadcyla followed by various Antibody Drug Conjugates (ADCs) in pipeline highlight the potential for new therapeutic innovations in the ADC industry.

According to this edition of the report “Global Antibody Drug Conjugate Market Outlook 2020”, the ADC market is anticipated to reach around US$ 12.7 Billion by 2020. In our report, there is a detailed analysis of the market for ADCETRIS and Kadcyla. An estimation of the market potential of these drugs has been done keeping in mind that these drugs are being tested in clinical trials for various indications, apart from the ones which are already approved. The mentioned ADCs will take some time to show their complete market potential, we believe.

Moreover, in our report we have provided information about the ADCs at various stages of clinical development. We have highlighted the various cancer indications that these ADCs target and the cytotoxic drugs that are commonly used for their development. Apart from this, the study provides comprehensive analysis of various ADCs in advanced stages of development. In addition, the report highlights the major drivers and challenges, latest trends and developments and strategic collaborations impacting the industry’s growth.

The latter part of the report discusses some of the prominent players in the ADC market. A brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Moreover, comparative analyses of their strengths and weaknesses have also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Antibody Drug Conjugate (ADC) – An Introduction
4. ADC Market Outlook to 2020
4.1 ADCETRIS
4.1.1 Market Potential
4.1.2 Market Size and Forecasts to 2020
4.2 Kadcyla
4.2.1 Market Potential
4.2.2 Market Size and Forecasts to 2020
5. ADC Pipeline Analysis
5.1 By Phase
5.2 By Indication
5.3 By Drug
6. Drivers and Challenges
6.1 Drivers
6.1.1 Advances in Linking Technologies Re-Instills Hope in ADC
6.1.2 Efforts towards Patent Protection to Drive ADC Market
6.2 Challenges
6.2.1 Production Hurdles and Cost
6.2.2 Inadequacy of Experienced Manufacturers
6.2.3 Regulatory Challenges
7. Current Status of Potential ADCs in Pipeline
7.1 Glembatumumab Vedotin Therapeutics /CDX-011 – Celldex
7.2 Coltuximab Ravtansine/SAR3419 – Immunogen Inc.
7.3 Indatuximab Ravtansine/BT-062 – Biotest
7.4 Anti-PSMA ADC Therapeutic – Progenics Pharmaceuticals
7.5 Polatuzumab Vedotin/RG7596 – Roche Genentech
7.6 Pinatuzumab Vedotin/RG7593 – Roche Genentech
7.7 Lifastuzumab Vedotin/RG7599 – Roche Genentech
7.8 Anti-guanylyl Cyclase C/Anti-GCC ADC – Takeda Millennium
7.9 Inotuzumab Ozogamicin (CMC-544) – Pfizer
8. Trends and Developments
8.1 ADC at the Forefront to Treat Hematological Malignancies
8.2 ADCs Providing Advantages to Breast Cancer Patients
9. Strategic Collaborations in the ADC Industry
10. Competitive Assessment
10.1 Seattle Genetics
10.2 Roche
10.3 Immunogen, Inc.
10.4 Bayer Healthcare
10.5 Novartis
10.6 Immunomedics
10.7 Agensys, Inc

List of Figures

Figure 3-1: ADC – Mechanism of Action
Figure 4-1: Global – ADC Market (Billion US$), 2014-2020
Figure 4-2: Global – ADCETRIS Market (Million US$), 2011-2013
Figure 4-3: Global – ADCETRIS Market (Billion US$), 2014-2020
Figure 4-4: Global – Kadcyla Market (Billion US$), 2014-2020
Figure 5-1: Pipeline ADCs by Clinical Phase (2014)
Figure 5-2: Pipeline ADCs by Indication (2014)
Figure 5-3: Pipeline ADCs by Drug (2014)

List of Tables

Table 4-1: Potential Patients for ADCETRIS (2012)
Table 4-2: Ongoing Trials for ADCETRIS
Table 4-3: Potential Patients for Kadcyla (2012)
Table 4-4: Ongoing Trials for Kadcyla
Table 7-1: ADCs in Pipeline
Table 9-1: Strategic Collaborations in ADC Industry
Table 10-1: Top Companies by ADCs in Pipeline (2014)
Table 10-2: Seattle Genetics – ADCs in Pipeline
Table 10-3: Seattle Genetics – ADCs Collaborator Pipeline
Table 10-4: Seattle Genetics – Strengths and Weaknesses
Table 10-5: Roche – ADC Collaborator Pipeline
Table 10-6: Roche – Strengths and Weaknesses
Table 10-7: Immunogen, Inc. – ADCs in Pipeline
Table 10-8: Immunogen, Inc. – ADC Collaborator Pipeline
Table 10-9: Immunogen, Inc. – Strengths and Weaknesses
Table 10-10: Bayer Healthcare – ADCs in Pipeline
Table 10-11: Bayer Healthcare – Strengths and Weaknesses
Table 10-12: Novartis Pharmaceuticals – ADCs in Pipeline
Table 10-13: Novartis Pharmaceuticals – Strengths and Weaknesses
Table 10-14: Immunomedics – ADCs in Pipeline
Table 10-15: Immunomedics – Strengths and Weaknesses
Table 10-16: Agensys, Inc. – ADC Collaborator Pipeline
Table 10-17: Agensys, Inc. – Strengths and Weaknesses



【レポートのキーワード】

抗体薬物複合体(ADC)、医薬品

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 抗体薬物複合体(ADC)のグローバル市場動向(Global Antibody Drug Conjugate Market Outlook 2020)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆